The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
Global X Genomics & Biotechnology ETF GNOM
Morningstar’s Analysis GNOM
Will GNOM outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 47.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Natera Inc | 8.04 | 7.3 Mil | Healthcare |
CRISPR Therapeutics AG | 5.16 | 4.7 Mil | Healthcare |
Moderna Inc | 4.94 | 4.5 Mil | Healthcare |
Ultragenyx Pharmaceutical Inc | 4.84 | 4.4 Mil | Healthcare |
Agilent Technologies Inc | 4.71 | 4.2 Mil | Healthcare |
Biomarin Pharmaceutical Inc | 3.97 | 3.6 Mil | Healthcare |
Sarepta Therapeutics Inc | 3.96 | 3.6 Mil | Healthcare |
Qiagen NV | 3.94 | 3.6 Mil | Healthcare |
Illumina Inc | 3.83 | 3.5 Mil | Healthcare |
Bio-Techne Corp | 3.72 | 3.4 Mil | Healthcare |